RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Robert Bitterman and Keith Brownlie have been appointed to the Company’s Board of Directors. Mr. Bitterman and Mr. Brownlie both bring extensive industry experience that will be instrumental to supporting RXi’s growth and development initiatives.
Mr. Bitterman brings over 18 years of leadership experience in the pharmaceutical and biologic life science industry to RXi. Mr. Bitterman currently serves as the President & CEO of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, LTD, a specialty pharma company focused on diseased and aging skin. Prior to Cutanea, he served as President and CEO for Isolagen, Inc., an international public, bioscience technology company whose primary proprietary platform used human fibroblasts for soft tissue enhancement. For 10 years, Mr. Bitterman served as the President and GM of Aventis' Dermik Laboratories, a global strategic business unit focused on therapeutic and aesthetic dermatology development and commercialization. “We are honored to have Robert join our Board of Directors,” said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that “His broad experience in the field of dermatology will be a valuable resource to RXi as we progress our first candidate into the clinic.”
Mr. Brownlie comes to RXi after a distinguished career with Ernst & Young that spanned 36 years. During his tenure, he rapidly became one of the leading accounting specialists for life sciences companies of the greater New York area. For the last 20 years at Ernst & Young, he has held the position of Metro New York Area Life Sciences Industry Leader. Mr. Brownlie has extensive experience with SEC registration statements, initial public offerings and recurrent reporting. In his accounting career he has been involved in over 100 public offerings. Until 2010, when he retired from Ernst & Young, he was a member of Ernst & Young’s National Life Sciences Committee, and he is a member of the American Institute of CPAs. Mr. Brownlie is currently a member of the Board of Directors of Epicept and Soligenix, where in both companies he also is chairman of the Audit Committee. “It is privilege for us at RXi to have someone of the caliber of Keith join RXi’s Board of Directors,” said Dr. Cauwenbergh. He added that “Keith joins us at a time that we expect to see RXi transform form a pure research platform company into a biotechnology product development company. His expertise will be beneficial in supporting and expediting this transition.”
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV